Inhaled nitric oxide inhibits platelet-leukocyte interactions in patients with acute respiratory distress syndrome

André Gries, Axel Herr, Sylvia Kirsch, Christine Günther, Steffen Weber, G. Szabó, Alexandra Holzmann, Bernd W. Böttiger, Eike Martin

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Introduction: In addition to its effects on platelet function, recent studies suggest that inhaled nitric oxide (NO) also influences the function of circulating leukocytes. Therefore, the aim of this work was to investigate the formation of platelet-leukocyte aggregates (PLAs) and platelet and leukocyte cell surface receptor expression during NO therapy in patients with acute respiratory distress syndrome. Methods: In 16 patients responding to NO therapy with an improvement in oxygenation (NO group) and in four nonresponders (control), platelet P-selectin expression, platelet fibrinogen binding, the expression CD11a on leukocytes, and the formation of PLAs were investigated at 0, 60, 120, and 180 mins of therapy or at corresponding time points by means of flow cytometry. In addition, PLA was investigated in 30 healthy volunteers during NO inhalation, in five mechanically ventilated patients without acute respiratory distress syndrome and without NO inhalation, and during NO incubation in platelet-rich plasma of ten healthy volunteers in vitro. Results: NO therapy inhibited PLA formation at 60 (13% ± 4% in the NO group vs. 19% ± 7% in the control group, p <.01) and 120 mins (14% ± 4% vs. 18% ± 7%, p <.05) and slightly decreased CD11a expression at 60 mins (152 ± 22 arbitrary units vs. 187 ± 36 arbitrary units, p <.05). Furthermore, besides inhibiting platelet fibrinogen binding, NO also led to a significant inhibition of P-selectin expression at 120 (38% ± 4% vs. 43% ± 5%, p <.05) and 180 mins (34% ± 5% vs. 43% ± 6%, p <.01), demonstrating a significant correlation between changes in P-selectin expression and PLA formation. In contrast, PLA formation was not influenced by mechanical ventilation in patients without acute respiratory distress syndrome. These results were further supported by additional studies showing inhibition of PLA formation in healthy volunteers as well. Conclusions: NO-dependent inhibition of PLA formation in patients with acute respiratory distress syndrome can be explained by the inhibition in platelet P-selectin expression. Thus, this study provides rational evidence of systemic antileukocytic and antiplatelet properties of NO therapy in the clinical setting.

Original languageEnglish
Pages (from-to)1697-1704
Number of pages8
JournalCritical Care Medicine
Volume31
Issue number6
DOIs
Publication statusPublished - Jun 1 2003

Fingerprint

Adult Respiratory Distress Syndrome
Nitric Oxide
Leukocytes
Blood Platelets
P-Selectin
Healthy Volunteers
Fibrinogen
Inhalation
Therapeutics
Platelet-Rich Plasma
Cell Surface Receptors
Artificial Respiration
Flow Cytometry

Keywords

  • Acute respiratory distress syndrome
  • Inhaled nitric oxide
  • Leukocytes
  • Platelets

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Inhaled nitric oxide inhibits platelet-leukocyte interactions in patients with acute respiratory distress syndrome. / Gries, André; Herr, Axel; Kirsch, Sylvia; Günther, Christine; Weber, Steffen; Szabó, G.; Holzmann, Alexandra; Böttiger, Bernd W.; Martin, Eike.

In: Critical Care Medicine, Vol. 31, No. 6, 01.06.2003, p. 1697-1704.

Research output: Contribution to journalArticle

Gries, A, Herr, A, Kirsch, S, Günther, C, Weber, S, Szabó, G, Holzmann, A, Böttiger, BW & Martin, E 2003, 'Inhaled nitric oxide inhibits platelet-leukocyte interactions in patients with acute respiratory distress syndrome', Critical Care Medicine, vol. 31, no. 6, pp. 1697-1704. https://doi.org/10.1097/01.CCM.0000063446.19696.D3
Gries, André ; Herr, Axel ; Kirsch, Sylvia ; Günther, Christine ; Weber, Steffen ; Szabó, G. ; Holzmann, Alexandra ; Böttiger, Bernd W. ; Martin, Eike. / Inhaled nitric oxide inhibits platelet-leukocyte interactions in patients with acute respiratory distress syndrome. In: Critical Care Medicine. 2003 ; Vol. 31, No. 6. pp. 1697-1704.
@article{1323f7d8e2a6439787b91f5e4b6c73b7,
title = "Inhaled nitric oxide inhibits platelet-leukocyte interactions in patients with acute respiratory distress syndrome",
abstract = "Introduction: In addition to its effects on platelet function, recent studies suggest that inhaled nitric oxide (NO) also influences the function of circulating leukocytes. Therefore, the aim of this work was to investigate the formation of platelet-leukocyte aggregates (PLAs) and platelet and leukocyte cell surface receptor expression during NO therapy in patients with acute respiratory distress syndrome. Methods: In 16 patients responding to NO therapy with an improvement in oxygenation (NO group) and in four nonresponders (control), platelet P-selectin expression, platelet fibrinogen binding, the expression CD11a on leukocytes, and the formation of PLAs were investigated at 0, 60, 120, and 180 mins of therapy or at corresponding time points by means of flow cytometry. In addition, PLA was investigated in 30 healthy volunteers during NO inhalation, in five mechanically ventilated patients without acute respiratory distress syndrome and without NO inhalation, and during NO incubation in platelet-rich plasma of ten healthy volunteers in vitro. Results: NO therapy inhibited PLA formation at 60 (13{\%} ± 4{\%} in the NO group vs. 19{\%} ± 7{\%} in the control group, p <.01) and 120 mins (14{\%} ± 4{\%} vs. 18{\%} ± 7{\%}, p <.05) and slightly decreased CD11a expression at 60 mins (152 ± 22 arbitrary units vs. 187 ± 36 arbitrary units, p <.05). Furthermore, besides inhibiting platelet fibrinogen binding, NO also led to a significant inhibition of P-selectin expression at 120 (38{\%} ± 4{\%} vs. 43{\%} ± 5{\%}, p <.05) and 180 mins (34{\%} ± 5{\%} vs. 43{\%} ± 6{\%}, p <.01), demonstrating a significant correlation between changes in P-selectin expression and PLA formation. In contrast, PLA formation was not influenced by mechanical ventilation in patients without acute respiratory distress syndrome. These results were further supported by additional studies showing inhibition of PLA formation in healthy volunteers as well. Conclusions: NO-dependent inhibition of PLA formation in patients with acute respiratory distress syndrome can be explained by the inhibition in platelet P-selectin expression. Thus, this study provides rational evidence of systemic antileukocytic and antiplatelet properties of NO therapy in the clinical setting.",
keywords = "Acute respiratory distress syndrome, Inhaled nitric oxide, Leukocytes, Platelets",
author = "Andr{\'e} Gries and Axel Herr and Sylvia Kirsch and Christine G{\"u}nther and Steffen Weber and G. Szab{\'o} and Alexandra Holzmann and B{\"o}ttiger, {Bernd W.} and Eike Martin",
year = "2003",
month = "6",
day = "1",
doi = "10.1097/01.CCM.0000063446.19696.D3",
language = "English",
volume = "31",
pages = "1697--1704",
journal = "Critical Care Medicine",
issn = "0090-3493",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Inhaled nitric oxide inhibits platelet-leukocyte interactions in patients with acute respiratory distress syndrome

AU - Gries, André

AU - Herr, Axel

AU - Kirsch, Sylvia

AU - Günther, Christine

AU - Weber, Steffen

AU - Szabó, G.

AU - Holzmann, Alexandra

AU - Böttiger, Bernd W.

AU - Martin, Eike

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Introduction: In addition to its effects on platelet function, recent studies suggest that inhaled nitric oxide (NO) also influences the function of circulating leukocytes. Therefore, the aim of this work was to investigate the formation of platelet-leukocyte aggregates (PLAs) and platelet and leukocyte cell surface receptor expression during NO therapy in patients with acute respiratory distress syndrome. Methods: In 16 patients responding to NO therapy with an improvement in oxygenation (NO group) and in four nonresponders (control), platelet P-selectin expression, platelet fibrinogen binding, the expression CD11a on leukocytes, and the formation of PLAs were investigated at 0, 60, 120, and 180 mins of therapy or at corresponding time points by means of flow cytometry. In addition, PLA was investigated in 30 healthy volunteers during NO inhalation, in five mechanically ventilated patients without acute respiratory distress syndrome and without NO inhalation, and during NO incubation in platelet-rich plasma of ten healthy volunteers in vitro. Results: NO therapy inhibited PLA formation at 60 (13% ± 4% in the NO group vs. 19% ± 7% in the control group, p <.01) and 120 mins (14% ± 4% vs. 18% ± 7%, p <.05) and slightly decreased CD11a expression at 60 mins (152 ± 22 arbitrary units vs. 187 ± 36 arbitrary units, p <.05). Furthermore, besides inhibiting platelet fibrinogen binding, NO also led to a significant inhibition of P-selectin expression at 120 (38% ± 4% vs. 43% ± 5%, p <.05) and 180 mins (34% ± 5% vs. 43% ± 6%, p <.01), demonstrating a significant correlation between changes in P-selectin expression and PLA formation. In contrast, PLA formation was not influenced by mechanical ventilation in patients without acute respiratory distress syndrome. These results were further supported by additional studies showing inhibition of PLA formation in healthy volunteers as well. Conclusions: NO-dependent inhibition of PLA formation in patients with acute respiratory distress syndrome can be explained by the inhibition in platelet P-selectin expression. Thus, this study provides rational evidence of systemic antileukocytic and antiplatelet properties of NO therapy in the clinical setting.

AB - Introduction: In addition to its effects on platelet function, recent studies suggest that inhaled nitric oxide (NO) also influences the function of circulating leukocytes. Therefore, the aim of this work was to investigate the formation of platelet-leukocyte aggregates (PLAs) and platelet and leukocyte cell surface receptor expression during NO therapy in patients with acute respiratory distress syndrome. Methods: In 16 patients responding to NO therapy with an improvement in oxygenation (NO group) and in four nonresponders (control), platelet P-selectin expression, platelet fibrinogen binding, the expression CD11a on leukocytes, and the formation of PLAs were investigated at 0, 60, 120, and 180 mins of therapy or at corresponding time points by means of flow cytometry. In addition, PLA was investigated in 30 healthy volunteers during NO inhalation, in five mechanically ventilated patients without acute respiratory distress syndrome and without NO inhalation, and during NO incubation in platelet-rich plasma of ten healthy volunteers in vitro. Results: NO therapy inhibited PLA formation at 60 (13% ± 4% in the NO group vs. 19% ± 7% in the control group, p <.01) and 120 mins (14% ± 4% vs. 18% ± 7%, p <.05) and slightly decreased CD11a expression at 60 mins (152 ± 22 arbitrary units vs. 187 ± 36 arbitrary units, p <.05). Furthermore, besides inhibiting platelet fibrinogen binding, NO also led to a significant inhibition of P-selectin expression at 120 (38% ± 4% vs. 43% ± 5%, p <.05) and 180 mins (34% ± 5% vs. 43% ± 6%, p <.01), demonstrating a significant correlation between changes in P-selectin expression and PLA formation. In contrast, PLA formation was not influenced by mechanical ventilation in patients without acute respiratory distress syndrome. These results were further supported by additional studies showing inhibition of PLA formation in healthy volunteers as well. Conclusions: NO-dependent inhibition of PLA formation in patients with acute respiratory distress syndrome can be explained by the inhibition in platelet P-selectin expression. Thus, this study provides rational evidence of systemic antileukocytic and antiplatelet properties of NO therapy in the clinical setting.

KW - Acute respiratory distress syndrome

KW - Inhaled nitric oxide

KW - Leukocytes

KW - Platelets

UR - http://www.scopus.com/inward/record.url?scp=0038806343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038806343&partnerID=8YFLogxK

U2 - 10.1097/01.CCM.0000063446.19696.D3

DO - 10.1097/01.CCM.0000063446.19696.D3

M3 - Article

C2 - 12794407

AN - SCOPUS:0038806343

VL - 31

SP - 1697

EP - 1704

JO - Critical Care Medicine

JF - Critical Care Medicine

SN - 0090-3493

IS - 6

ER -